What We Do
Commitment to Innovation
ET-traps therapeutic targets pathologically elevated endothelin-1 levels in the body bringing endothelin-1 and various markers of heart and kidney function back to non-disease levels without side effects.
Drug Development
We believe we have discovered a potent therapy for cardiovascular disease, chronic kidney disease and other diseases like diabetes and neurological disorders that are associated with pathologically elevated ET-1 levels with a low cost, low dosage drug with no side effects.